IGF2 and neoplasm: Tissue samples obtained from responders undergoing anti–CTLA-4 and anti–PD-1 therapy exhibited decreased levels of IGF2 expression within the mammary T11 tumor in comparison with the control group (Supplemental Figure 10A).